TMO

EX-99.1

2 q22026earnings8kex99_1.htm

EX-99.1

Document

Exhibit 99.1

News

Media Contact Information:

Sandy Pound

Thermo Fisher Scientific

Investor Contact Information:

Rafael Tejada

Thermo Fisher Scientific

Phone: 781-622-1223

Phone: 781-622-1356

E-mail: sandy.pound@thermofisher.com

E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Reports Second Quarter 2026 Results

Revenue Grew 10% Including 5% Organic Revenue Growth

Grew GAAP Diluted EPS 9% and Adjusted EPS 13%

Customer Activity Across Our End Markets Continued to Strengthen

WALTHAM, Mass. (July 23, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026.

Second Quarter Highlights

•Second quarter revenue grew 10% to $11.99 billion

•Second quarter GAAP diluted earnings per share (EPS) grew 9% to $4.68

•Second quarter adjusted EPS grew 13% to $6.03

“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellent execution and the power of our PPI Business System,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “Our end markets continue to strengthen and we're making great progress enhancing our capabilities, and further advancing our trusted partner status with customers, leading to continued share gain.”

Casper added, “At the halfway point of the year, we are well positioned to deliver a great 2026 and build an even brighter future for our company.”

Growth Strategy and Capital Deployment

•Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. At the American Society for Mass Spectrometry conference, we introduced next-generation Orbitrap platforms with AI-driven analytics. Highlights include the Thermo Scientific™ Orbitrap™ Tribrid™ Apex Mass Spectrometer, which enables researchers to study complex biology across multiomics, structural biology, biopharma characterization and small-molecule analysis on a single system, and the Thermo Scientific™ Orbitrap™ Excedion™ Mass Spectrometer, which enables scientists to identify hard-to-detect molecules in drug development, reducing risk and accelerating time to market. We also introduced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation PCR system designed to improve workflow flexibility, speed and reproducibility for molecular biology laboratories.

•Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers. During the quarter, we opened our flagship U.S. Bioprocess Design Center in Plainville, Massachusetts, expanding our global network of collaborative innovation hubs enabling pharma and biotech customers to accelerate drug development and optimize manufacturing. We also announced a strategic collaboration with Precision Health Research, Singapore to support the PRECISE-SG100K population health study, leveraging our integrated proteomics capabilities, including Olink® technology and the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometry system, to advance precision medicine.

•Continued to successfully execute our capital deployment strategy. During the quarter, we announced the divestiture of our microbiology business and repurchased $1.0 billion of stock.

Financial Results

Revenue for the second quarter of 2026 grew 10% to $11.99 billion, versus $10.85 billion in the same quarter of 2025. Organic revenue growth was 5%.

GAAP Earnings Results

GAAP diluted EPS in the second quarter of 2026 was $4.68, 9% growth versus the second quarter of 2025. GAAP operating income for the second quarter of 2026 was $2.09 billion, 14% higher than the year-ago quarter. GAAP operating margin was 17.4%, compared with 16.9% in the second quarter of 2025.

Non-GAAP Earnings Results

Adjusted EPS for the second quarter of 2026 was $6.03, 13% growth versus the second quarter of 2025. Adjusted operating income for the second quarter of 2026 was $2.73 billion, 15% higher than the year-ago quarter. Adjusted operating margin was 22.8%, compared with 21.9% in the second quarter of 2025.

Annual Guidance for 2026

The company will provide updated 2026 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.

Use of Non-GAAP Financial Measures

Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, and organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.

Note on Presentation

Certain amounts and percentages reported within this press release are presented and calculated based on unde

EX-99.1

2 q12026earnings8kex99_1.htm

EX-99.1

Document

Exhibit 99.1

News

Media Contact Information:

Sandy Pound

Thermo Fisher Scientific

Investor Contact Information:

Rafael Tejada

Thermo Fisher Scientific

Phone: 781-622-1223

Phone: 781-622-1356

E-mail: sandy.pound@thermofisher.com

E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Reports First Quarter 2026 Results

WALTHAM, Mass. (April 23, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

First Quarter Highlights

•First quarter revenue grew 6% to $11.01 billion.

•First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43.

•First quarter adjusted EPS grew 6% to $5.44.

•Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company.

•Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included the Thermo Scientific™ Glacios™ 3 Cryo-TEM, a next-generation cryo-transmission electron microscope designed to enable installation in a broader range of lab spaces, democratizing access to cryo-EM for use in structural biology; the Thermo Scientific™ TSQ Certis™ triple quadrupole mass spectrometer, which enhances productivity and reliability by delivering faster, high-quality results to support analytical testing across pharmaceutical and applied laboratories; the Thermo Scientific™ Niton™ XL5e Handheld XRF Analyzer, which enables industrial and applied customers to improve the speed and accuracy of identifying materials in the field; and the Gibco™ CTS™ Compleo™ Fill and Finish System, which increases productivity and reliability in cell therapy manufacturing, supporting scalable production of advanced therapies.

•Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers. During the quarter, we announced a strategic collaboration with NVIDIA, combining our leadership in laboratory technologies with NVIDIA’s AI capabilities to advance scientific instrumentation, improve laboratory performance and accelerate scientific breakthroughs. We also announced a strategic collaboration with SHL Medical to deliver fully integrated sterile fill-finish and device assembly solutions, advancing our U.S. drug product manufacturing capabilities and helping pharma and biotech customers accelerate development and commercialization of important medicines.

•Continued to successfully execute our capital deployment strategy. During the quarter, we completed the acquisition of Clario, an industry-leading provider of endpoint data solutions, repurchased $3.0 billion of stock and increased our dividend by 10%.

“We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational excellence and enable our customers’ success,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “We continued to make great progress executing our strategy, further strengthening our capabilities with the addition of Clario.”

Casper added, “Looking ahead, we are well positioned to deliver a strong year. As the trusted partner to our customers, we are uniquely equipped to help them accelerate their innovation and enhance their productivity. Through our global scale and the power of the PPI Business System, we will continue to actively manage the company to create value for our stakeholders and build an even brighter future for our company."

First Quarter 2026

Revenue for the first quarter of 2026 grew 6% to $11.01 billion, versus $10.36 billion in the same quarter of 2025. Organic revenue growth was 1%.

GAAP Earnings Results

GAAP diluted EPS in the first quarter of 2026 was $4.43, 11% growth versus the first quarter of 2025. GAAP operating income for the first quarter of 2026 was $1.86 billion, 9% higher than the year-ago quarter. GAAP operating margin was 16.9%, compared with 16.6% in the first quarter of 2025.

Non-GAAP Earnings Results

Adjusted EPS for the first quarter of 2026 was $5.44, 6% growth versus the first quarter of 2025. Adjusted operating income for the first quarter of 2026 was $2.40 billion, 6% higher than the year-ago quarter. Adjusted operating margin was 21.8%, compared with 21.9% in the first quarter of 2025.

Annual Guidance for 2026

The company will provide updated 2026 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.

Use of Non-GAAP Financial Measures

Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, and organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Suppleme

tmo-202601290000097745FALSE00000977452026-01-292026-01-290000097745us-gaap:CommonStockMember2026-01-292026-01-290000097745tmo:A1.45SeniorNotesDue2027Member2026-01-292026-01-290000097745tmo:SeniorNotes175Due2027Member2026-01-292026-01-290000097745tmo:FloatingRateNotesDue2027Member2026-01-292026-01-290000097745tmo:SeniorNotes0.500Due2028Member2026-01-292026-01-290000097745tmo:SeniorNotes1.375Due2028Member2026-01-292026-01-290000097745tmo:SeniorNotes1.95Due2029Member2026-01-292026-01-290000097745tmo:SeniorNotes0.875Due2031Member2026-01-292026-01-290000097745tmo:SeniorNotes2375Due2032Member2026-01-292026-01-290000097745tmo:SeniorNotes3650Due2034Member2026-01-292026-01-290000097745tmo:SeniorNotes3.628Due2035Member2026-01-292026-01-290000097745tmo:SeniorNotes2.875Due2037Member2026-01-292026-01-290000097745tmo:SeniorNotes1.500Due2039Member2026-01-292026-01-290000097745tmo:SeniorNotes1.875Due2049Member2026-01-292026-01-29

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its Charter)

Delaware1-800204-2209186 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

168 Third Avenue Waltham, Massachusetts 02451 (Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $1.00 par valueTMONew York Stock Exchange 1.450% Notes due 2027TMO 27New York Stock Exchange 1.750% Notes due 2027TMO 27BNew York Stock Exchange Floating Rate Notes due 2027TMO 27DNew York Stock Exchange 0.500% Notes due 2028TMO 28ANew York Stock Exchange 1.375% Notes due 2028TMO 28New York Stock Exchange 1.950% Notes due 2029TMO 29New York Stock Exchange 0.875% Notes due 2031TMO 31New York Stock Exchange 2.375% Notes due 2032TMO 32New York Stock Exchange 3.650% Notes due 2034TMO 34New York Stock Exchange 3.628% Notes due 2035TMO 35ANew York Stock Exchange 2.875% Notes due 2037TMO 37New York Stock Exchange 1.500% Notes due 2039TMO 39New York Stock Exchange 1.875% Notes due 2049TMO 49New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02    Results of Operations and Financial Condition.

On January 29, 2026, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

99.1 Press Release dated January 29, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERMO FISHER SCIENTIFIC INC.

Date:January 29, 2026By:/s/ Joseph R. Holmes Joseph R. Holmes Vice President and Chief Accounting Officer

3